drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Patient-derived T cells genetically engineered ex vivo to express a chimeric antigen receptor recognizing TM4SF1 on tumor cells, leading to T-cell activation, cytokine release, and cytotoxic killing of TM4SF1-expressing cancer cells. The CAR construct includes an EGFR-based safety switch. Administered via IV or local infusion with dose escalation (0.5–10×10^6 cells/kg).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous, Local injection
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a chimeric antigen receptor that binds TM4SF1 on tumor cells. Antigen engagement triggers CAR signaling, leading to T‑cell activation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of TM4SF1‑expressing cancer cells. An EGFR-based safety switch enables targeted elimination of the CAR T cells if required.
drug_name
Autologous TM4SF1-targeted CAR T cells
nct_id_drug_ref
NCT05673434